European Heart Journal Advance Access published online on February 8, 2007
European Heart Journal, doi:10.1093/eurheartj/ehl518
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
The cost of implantable defibrillators: how the perception of reality depends on perspective
University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
* Corresponding author. Tel: +32 16 34 42 48; fax: +32 16 34 42 40. E-mail address: hein.heidbuchel@uz.kuleuven.ac.be
This editorial refers to The high cost of implantable defibrillators by M.A. Hlatky and D.B. Mark, doi:10.1093/eurheartj/ehl311 and The cost of implantable defibrillators: perceptions and reality by J. Camm et al., doi:10.1093/eurheartj/ehl166
| The first 150 words of the full text of this article appear below. |
The implantable cardioverter defibrillator (ICD) has been the subject of controversy since its very inception. Although Michel Mirowski had a visionary idea about how implantable devices could prevent arrhythmic sudden death, his vision immediately met criticism. Twenty-five years later, the skepticism has moved from issues of feasibility and effectiveness, raised by colleagues, to questions about cost and cost-effectiveness, asked by society. The discussion shows the evolution from evidence-based to value-based medicine.1 By entering the health-economic arena, arguments have evolved from medically and scientific to economic and even ethical, where standards for evaluation are much less well defined than outcomes of randomized trials.
Two opinion papers in this issue of the journal2,3 illustrate the persisting controversy around ICD therapy and its current stage. Both agree on the evidence that secondary ICD implantation (i.e. after a prior cardiac arrest or haemodynamically compromising ventricular tachycardia) and prophylactic ICD implantation in patients with compromised
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- The cost of implantable defibrillators: perceptions and reality
- John Camm, Helmut Klein, and Seah Nisam
EHJ 2007 28: 392-397.[Abstract] [FREE Full Text]
This article has been cited by other articles:
![]() |
J. B. Johansen, S. S. Pedersen, H. Spindler, K. Andersen, J. C. Nielsen, and P. T. Mortensen Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: a single-centre, cross-sectional study in 610 patients Europace, May 1, 2008; 10(5): 545 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Kristensen, H. Baumgartner, H. Drexler, E. Eeckhout, G. Filippatos, A. K. Gitt, C. Linde, L. A. Pierard, D. Poldermans, H. Schunkert, et al. Highlights of the 2007 Scientific Sessions of the European Society of Cardiology: Vienna, Austria, September 1 5, 2007 J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2421 - 2430. [Full Text] [PDF] |
||||

